Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: A randomised, double-blind, placebo-controlled study

Bee See Goh, M. I M Ismail, Salina Husain

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

Original languageEnglish
Pages (from-to)242-248
Number of pages7
JournalJournal of Laryngology and Otology
Volume128
Issue number3
DOIs
Publication statusPublished - 12 Mar 2014

Fingerprint

montelukast
Steroids
Placebos
Quality of Life
Tablets
Nasal Sprays
Loratadine
Allergic Rhinitis
Therapeutics

Keywords

  • Allergic Rhinitis
  • Fluticasone Propionate
  • Montelukast
  • Quality Of Life

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Medicine(all)

Cite this

@article{14d2be4c47514e90a8db8fe7551eae43,
title = "Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: A randomised, double-blind, placebo-controlled study",
abstract = "Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.",
keywords = "Allergic Rhinitis, Fluticasone Propionate, Montelukast, Quality Of Life",
author = "Goh, {Bee See} and Ismail, {M. I M} and Salina Husain",
year = "2014",
month = "3",
day = "12",
doi = "10.1017/S002221511400036X",
language = "English",
volume = "128",
pages = "242--248",
journal = "Journal of Laryngology and Otology",
issn = "0022-2151",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids

T2 - A randomised, double-blind, placebo-controlled study

AU - Goh, Bee See

AU - Ismail, M. I M

AU - Husain, Salina

PY - 2014/3/12

Y1 - 2014/3/12

N2 - Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

AB - Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

KW - Allergic Rhinitis

KW - Fluticasone Propionate

KW - Montelukast

KW - Quality Of Life

UR - http://www.scopus.com/inward/record.url?scp=84922017358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922017358&partnerID=8YFLogxK

U2 - 10.1017/S002221511400036X

DO - 10.1017/S002221511400036X

M3 - Article

C2 - 24618303

AN - SCOPUS:84922017358

VL - 128

SP - 242

EP - 248

JO - Journal of Laryngology and Otology

JF - Journal of Laryngology and Otology

SN - 0022-2151

IS - 3

ER -